StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)

Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%

Latigo Biotherapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$20.95M–
Q2 FY2026Jun 30, 2026-$25.80M–
Q1 FY2026Mar 31, 2026-$22.96M–
Q3 FY2025Sep 30, 2025-$24.80M–
Q2 FY2025Jun 30, 2025-$25.84M–
Q1 FY2025Mar 31, 2025-$20.95M–

More Latigo Biotherapeutics figures

See a number that looks wrong?